Immunome's Chief Scientist Trimmed His Stake. A Planned FDA Submission Tells You More
9,438 shares were sold for a transaction value of ~$204,000 on April 2, 2026. This sale represented 30.02% of Higgins's holdings at the time.
Immunome (IMNM) Moves 13.3% Higher: Will This Strength Last?
Immunome (IMNM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Immunome: Upcoming NDA, Valuation, And Investment Case
Immunome is advancing varegacestat for desmoid tumors, targeting NDA submission in Q2 2026 after positive phase 3 RINGSIDE data. Varegacestat demonstrated superior efficacy and safety versus nirogacestat, with an 84% risk reduction in progression or death and a 56% objective response rate. Despite a small addressable market (~3,000 patients), conservative peak global sales are estimated at $280 million, supporting a valuation over 235% above IMNM's current market cap.
Immunome: Maintaining "Strong Buy" On Successful RINGSIDE Trial With Varegacestat
Immunome (IMNM) delivered statistically significant phase 3 RINGSIDE results for varegacestat in progressive desmoid tumors, achieving an 84% risk reduction in progression or death compared to placebo. Varegacestat demonstrated a 56% objective response rate, the highest ever in a randomized desmoid tumor trial, and a marked reduction in tumor volume. I maintain a "Strong Buy" rating, supported by the upcoming NDA filing for varegacestat in Q2 2026 and IM-1021's phase 1 lymphoma data expected in 2026.
Immunome's experimental drug meets main goal in late-stage study
Immunome said on Monday its experimental drug met main goal in a late-stage study for patients with a rare type of tumor.
Immunome: SpringWorks Buyout Informs The Potential Upside Here
Immunome's lead asset, varegacestat, shows promising efficacy in desmoid tumors, with phase 3 topline data expected by the end of 2025. IMNM holds Orphan Drug designations in the US and Europe, potentially enabling accelerated approval if phase 3 results are positive. Cash reserves of $143.9M and marketable securities of $124.2M provide runway into 2027, despite a high annualized cash burn.
Immunome, Inc. (IMNM) Reports Q2 Loss, Beats Revenue Estimates
Immunome, Inc. (IMNM) came out with a quarterly loss of $0.5 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to a loss of $0.49 per share a year ago.
Immunome (IMNM) Soars 6.0%: Is Further Upside Left in the Stock?
Immunome (IMNM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Immunome (IMNM) Upgraded to Buy: Here's What You Should Know
Immunome (IMNM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts See a 158.17% Upside in Immunome (IMNM): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 158.2% in Immunome (IMNM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts Think Immunome (IMNM) Could Surge 188.57%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 188.6% in Immunome (IMNM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
All You Need to Know About Immunome (IMNM) Rating Upgrade to Buy
Immunome (IMNM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
